Outlook Therapeutics Inc.
Organization details
- Legal name
- Outlook Therapeutics Inc.
- Former names
- Oncobiologics, Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Iselin
- Headquarters state / province
- New Jersey
- Headquarters country
- United States
- Fiscal year end
- September
- Ticker symbol
- OTLK
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001649989
- EIN
- 38-3982704
Board of directors
-
Andong Huang · DirectorSince 2023
-
C. Russell Trenary III · Director · CEO AND PRESIDENTSince 2023
-
Faisal Ghiath Sukhtian · DirectorSince 2023
-
Gerd Auffarth · DirectorSince 2023
-
Ghiath M. Sukhtian · DirectorSince 2024
-
Julia A. Haller · DirectorSince 2023
-
Julian S. Gangolli · DirectorSince 2023
-
Kurt J. Hilzinger · DirectorSince 2023
-
Lawrence A. Kenyon · Director · Chief Financial OfficerSince 2024
-
Randy H. Thurman · DirectorSince 2023
-
Robert Charles Jahr · Director · Chief Executive OfficerSince 2026
-
Yezan Munther Haddadin · DirectorSince 2023
Chief executives
Director election results
Annual meeting of March 10, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
91.4%
-
92.4%
-
93.7%
Board connections
3 of this board's directors also sit on 3 other boards. 2 are in the same sector.
-
Bristol-Myers Squibb Company Same sectorvia Julia A. Haller
- via Kurt J. Hilzinger
-
Krystal Biotech Inc. Same sectorvia Julian S. Gangolli
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $7,905,867
- 10 purchases by 8 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 14, 2026 | Robert Charles Jahr Director, Officer (Chief Executive Officer) | Open-market purchase | +151,515 | — | — |
| Aug 14, 2026 | Lawrence A. Kenyon Director, Officer (Chief Financial Officer) | Open-market purchase | +101,010 | — | — |
| Aug 12, 2026 | Ghiath M. Sukhtian Director, 10% owner | Open-market purchase | +2,525,252 | $0.99 | $2,499,999 |
| Jul 29, 2026 | Faisal Ghiath Sukhtian Director | Open-market purchase | +95,398 | $1.05 | $100,168 |
| Jun 2, 2026 | Yezan Munther Haddadin Director | Open-market purchase | +29,000 | $0.83 | $24,070 |
| May 28, 2026 | GMS Ventures & Investments Director, 10% owner | Open-market purchase | +8,539,709 | $0.59 | $5,038,428 |
| May 27, 2026 | Faisal Ghiath Sukhtian Director | Open-market purchase | +122,174 | $0.41 | $50,091 |
| May 26, 2026 | Yezan Munther Haddadin Director | Open-market purchase | +34,000 | $0.44 | $14,960 |
| May 26, 2026 | Randy H. Thurman Director | Open-market purchase | +5,000 | $0.43 | $2,150 |
| May 26, 2026 | Kurt J. Hilzinger Director | Open-market purchase | +400,000 | $0.44 | $176,000 |
| May 27, 2025 | Ghiath M. Sukhtian Director, 10% owner | Grant or award | +4,285,714 | $1.40 | $6,000,000 |
| Sep 26, 2024 | Lawrence A. Kenyon Director, Officer (Chief Financial Officer) | Open-market purchase | +5,000 | $5.69 | $28,450 |
| Apr 15, 2024 | Syntone Ventures LLC 10% owner | Open-market purchase | +714,286 | — | — |
| Mar 28, 2024 | Yezan Munther Haddadin Director | Open-market purchase | +1,882 | $11.82 | $22,242 |
| Mar 18, 2024 | Ghiath M. Sukhtian Director, 10% owner | Grant or award | +2,305,714 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Outlook Therapeutics Inc.
Who is the CEO of Outlook Therapeutics Inc.?
C. Russell Trenary III is Outlook Therapeutics Inc.'s CEO and President.
How many directors are on Outlook Therapeutics Inc.'s board?
Outlook Therapeutics Inc.'s board has 12 directors: Andong Huang, C. Russell Trenary III, Faisal Ghiath Sukhtian, Gerd Auffarth, Ghiath M. Sukhtian, Julia A. Haller, Julian S. Gangolli, Kurt J. Hilzinger, Lawrence A. Kenyon, Randy H. Thurman and 2 others.
Are Outlook Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Outlook Therapeutics Inc. insiders bought $7.9 million of shares in 10 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="outlook-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.